Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline(updated version)  

作　　者：Ying-Hui Jin Qing-Yuan Zhan Zhi-Yong Peng Xue-Qun Ren Xun-Tao Yin Lin Cai Yu-Feng Yuan Ji-Rong Yue Xiao-Chun Zhang Qi-Wen Yang Jianguang Ji Jian Xia Yi-Rong Li Fu-Xiang Zhou Ya-Dong Gao Zhui Yu Feng Xu Ming-Li Tu Li-Ming Tan Min Yang Fang Chen Xiao-Ju Zhang Mei Zeng Yu Zhu Xin-Can Liu Jian Yang Dong-Chi Zhao Yu-Feng Ding Ning Hou Fu-Bing Wang Hao Chen Yong-Gang Zhang Wei Li Wen Chen Yue-Xian Shi Xiu-Zhi Yang Xue-Jun Wang Yan-Jun Zhong Ming-Juan Zhao Bing-Hui Li Lin-Lu Ma Hao Zi Na Wang Yun-Yun Wang Shao-Fu Yu Lu-Yao Li Qiao Huang Hong Weng Xiang-Ying Ren Li-Sha Luo Man-Ru Fan Di Huang Hong-Yang Xue Lin-Xin Yu Jin-Ping Gao Tong Deng Xian-Tao Zeng Hong-Jun Li Zhen-Shun Cheng Xiao-Mei Yao Xing-Huan Wang 

机构地区：[1]Center for Evidence-Based and Translational Medicine,Zhongnan Hospital of Wuhan University,Wuhan 430071,China [2]National Clinical Research Center for Respiratory Diseases,China-Japan Friendship Hospital,Beijing 100029,China [3]Department of Pulmonary and Critical Care Medicine,China-Japan Friendship Hospital,Beijing 10029,China [4]Leishenshan Hospital in Wuhan,Wuhan 430200,China [5]Department of Critical Care Medicine,Zhongnan Hospital of Wuhan University,Wuhan 430071,China [6]Institutes of Evidence-based Medicine and Knowledge Translation,Henan University,Kaifeng 475000,Henan,China [7]Department of Medical Imaging,Guizhou Provincial People’s Hospital,Guiyang 550002,China [8]Departments of Orthopedics,Zhongnan Hospital of Wuhan University,Wuhan 430071,China [9]Department of Hepatobiliary Surgery,Zhongnan Hospital of Wuhan University,Wuhan 430071,China [10]National Clinical Research Center for Geriatrics,West China Hospital of Sichuan University,Chengdu 610041,China [11]Department of Geriatrics,West China Hospital of Sichuan University,Chengdu 610041,China [12]Department of Radiology,Zhongnan Hospital of Wuhan University,Wuhan 430071,China [13]Department of Clinical Laboratory,Peking Union Medical College Hospital(PUMCH),Peking Union Medical College,Chinese Academy of Medical Sciences(CAMS),Beijing 100730,China [14]Center for Primary Health Care Research,Lund University and Region Skåne,25002 Malmö,Sweden [15]Emergency Center,Zhongnan Hospital of Wuhan University,Wuhan 403371,China [16]Department of Allergology,Zhongnan Hospital of Wuhan University,Wuhan 430071,China [17]Department of Radiation and Medical Oncology,Zhongnan Hospital of Wuhan University,Wuhan 43071,China [18]Department of Critical Care Medicine,Renmin Hospital of Wuhan University,Wuhan 430060,China [19]Department of Emergency Medicine and Chest Pain Center,Qilu Hospital of Shandong University,Jinan 250002,China [20]Department of Respiratory and Critical Care Medicine,Suizhou Central Hospital,Hubei University of Medicine,Suizhou 441300,Hubei

出　　处：《Military Medical Research》2020年第3期249-282,共34页军事医学研究（英文版）

基　　金：supported(in part)by the National Key Research and Development Program of China(2020YFC0845500);the Special Project for Emergency of Hubei Province(2020FCA008);the First Level Funding of the Second Medical Leading Talent Project in Hubei Province。

摘　　要：The novel severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is the cause of a rapidly spreading illness,coronavirus disease 2019(COVID-19),affecting more than seventeen million people around the world.Diagnosis and treatment guidelines for clinicians caring for patients are needed.In the early stage,we have issued"A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus(2019-nCoV)infected pneumonia(standard version)";now there are many direct evidences emerged and may change some of previous recommendations and it is ripe for develop an evidence-based guideline.We formed a working group of clinical experts and methodologists.The steering group members proposed 29 questions that are relevant to the management of COVID-19 covering the following areas:chemoprophylaxis,diagnosis,treatments,and discharge management.We searched the literature for direct evidence on the management of COVID-19,and assessed its certainty generated recommendations using the Grading of Recommendations,Assessment,Development and Evaluation(GRADE)approach.Recommendations were either strong or weak,or in the form of ungraded consensus-based statement.Finally,we issued 34 statements.Among them,6 were strong recommendations for,14 were weak recommendations for,3 were weak recommendations against and 11 were ungraded consensus-based statement.They covered topics of chemoprophylaxis(including agents and Traditional Chinese Medicine(TCM)agents),diagnosis(including clinical manifestations,reverse transcription-polymerase chain reaction(RT-PCR),respiratory tract specimens,IgM and IgG antibody tests,chest computed tomography,chest X-ray,and CT features of asymptomatic infections),treatments(including lopinavirritonavir,umifenovir,favipiravir,interferon,remdesivir,combination of antiviral drugs,hydroxychloroquine/chloroquine,interleukin-6 inhibitors,interleukin-1 inhibitors,glucocorticoid,qingfei paidu decoction,lianhua qingwen granules/capsules,convalescent plasma,lung transplantation,invasive or noninvasive ventilat

关 键 词：COVID-19 SARS-CoV-2 Recommendation CHEMOPROPHYLAXIS DIAGNOSIS Treatment Discharge management Traditional Chinese medicine GUIDELINE 

分 类 号：R563.1[医药卫生—呼吸系统]